<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20598" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Disopyramide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sundjaja</surname>
            <given-names>Joshua Henrina</given-names>
          </name>
          <aff>Atma Jaya Catholic University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Makaryus</surname>
            <given-names>Amgad N.</given-names>
          </name>
          <aff>Donald and Barbara Zucker School Medicine at Hofstra/Northwell</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Henrina Sundjaja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amgad Makaryus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20598.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Disopyramide is a medication used to treat heart rhythm abnormalities, which can be life-threatening, such as ventricular tachycardia/fibrillation or associated with increased morbidity and mortality like atrial fibrillation and hypertrophic cardiomyopathy. This activity reviews several important aspects of this drug, including the indications, mechanism of actions, administrations, adverse events, contraindications, monitoring, and toxicity. This important information regarding this drug can enhance interprofessional healthcare team outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of disopyramide.</p></list-item><list-item><p>Describe the potential adverse effects of disopyramide.</p></list-item><list-item><p>Explain the importance of monitoring when using disopyramide as an antiarrhythmic drug.</p></list-item><list-item><p>Outline the interprofessional team strategies for improving care coordination and communication when using disopyramide to maximize the benefits of this drug and minimize its side effects.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20598&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20598">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20598.s2" sec-type="Indications">
        <title>Indications</title>
        <p>In 1962, there was a need for new antiarrhythmic drugs other than quinidine and procainamide, the main available antiarrhythmic agents available at that time. From more than 500 compounds synthesized for the research program of new antiarrhythmic agents, disopyramide is the selected agent. The chemical structures of disopyramide resemble the synthetic muscarinic antagonist, lachesine, which explained&#x000a0;its anticholinergic property.<xref ref-type="bibr" rid="article-20598.r1">[1]</xref></p>
        <p>Despite&#x000a0;rarely used now for heart rhythm abnormalities because of the availability of newer drugs&#x000a0;that provided&#x000a0;better efficacy and favorable side effect profiles, disopyramide is still the drug of choice for vagally mediated atrial fibrillation such as sleep-induced or atrial fibrillation in athlete groups.<xref ref-type="bibr" rid="article-20598.r2">[2]</xref>&#x000a0;The effectivity of disopyramide in these conditions is due to its anticholinergic activity that abolished parasympathetic tone.<xref ref-type="bibr" rid="article-20598.r3">[3]</xref>&#x000a0;</p>
        <p>It is also a third-line antiarrhythmic agent for a patient with coronary artery disease. Moreover, in a patient with left ventricular hypertrophy, there is&#x000a0;impaired depolarization, which can induce torsade de pointes. Hence, antiarrhythmics that prolong QT interval are avoided, but if sotalol or amiodarone either fail or are inappropriate, disopyramide can be an alternative.<xref ref-type="bibr" rid="article-20598.r4">[4]</xref> In a patient with atrial fibrillation and hypertrophic obstructive cardiomyopathy (HOCM), disopyramide is the selected agent other than amiodarone because it can decrease the left ventricular outflow tract (LVOT) gradient (off-label use).<xref ref-type="bibr" rid="article-20598.r4">[4]</xref><xref ref-type="bibr" rid="article-20598.r5">[5]</xref>&#x000a0;Data from the multicenter study of safety and efficacy of disopyramide in obstructive cardiomyopathy showed that disopyramide significantly decreases&#x000a0;(P&#x0003c;0.0001) the LVOT gradient from 75+/- 33 to 40+/-32 mmHg in 78 patients&#x000a0;(66% of the study subjects) and improves New York Heart Association functional class (NYHA FC) from 23+/-07 to 17+/-06( P&#x0003c;0.0001).<xref ref-type="bibr" rid="article-20598.r5">[5]</xref> When using disopyramide in combination non-dihydropyridine calcium channel blocker or beta-blocker, they can effectively prevent the recurrence of AF in HCOM patients.<xref ref-type="bibr" rid="article-20598.r2">[2]</xref>&#x000a0;</p>
        <p>A high symptom burden can be present in patients with a ventricular premature beat (VPB) or premature ventricular complexes (PVC). Disopyramide can be used for patients without&#x000a0;structural heart disease can&#x000a0;be treated with, albeit their efficacy is lower compared to ablation.<xref ref-type="bibr" rid="article-20598.r6">[6]</xref>&#x000a0;Additionally, based on&#x000a0;a&#x000a0;randomized, double-blind placebo-controlled one year follow up study, disopyramide (n=44) is effective in maintaining sinus rhythm after electro cardioversion for atrial fibrillation compared to placebo (n= 46), and it is significantly different at one-month follow-up (70% vs. 39%) and persist after&#x000a0;twelve months (54% vs. 30%).<xref ref-type="bibr" rid="article-20598.r7">[7]</xref></p>
      </sec>
      <sec id="article-20598.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>According to the Vaughan Williams classification, antiarrhythmic drugs classify into&#x000a0;five main classes based on their mechanism of action. The class I antiarrhythmic works mainly by blocking the sodium ion channels, which are responsible for the fast inward depolarizing current of the cardiomyocytes. This classification then&#x000a0;is grouped again according to their effect on the length of the action potential of the cardiomyocyte to Ia., Ib, and 1c, with the type Ic. is the strongest. The type Ib is the weakest with respect to its binding affinity to the sodium channels.<xref ref-type="bibr" rid="article-20598.r8">[8]</xref>&#x000a0;Disopyramide is an antiarrhythmic drug that belongs to class Ia.&#x000a0;As with other class&#x000a0;I&#x000a0;antiarrhythmic drugs, such as quinidine, ajmaline, and procainamide, the mechanism of action of disopyramide is to lengthen the action potential duration (APD) of cardiomyocytes, reflected by the rightward shift of the action potential curve. It also lowers the rate of diastolic depolarization (phase 4) in cells with augmented automaticity and the upstroke velocity (phase 1).<xref ref-type="bibr" rid="article-20598.r9">[9]</xref> Therefore, disopyramide decreases myocardial excitability and conduction velocity</p>
        <p>Compared to the ischemic myocardium, the normally perfused adjacent myocardia display a minimal difference in refractoriness due to APD lengthening hence&#x000a0;disopyramide's protective effect from the reentry phenomenon. On the contrary, although theoretically useful to prevent reentry phenomenon from ischemic myocardia, a multicenter, double-blind, randomized study involving 1985 subjects (n treatment = 995, n placebo= 990 ) evaluating oral disopyramide for patients admitted due to myocardial infarction (MI) found that there is no decrease in mortality rate.<xref ref-type="bibr" rid="article-20598.r10">[10]</xref>&#x000a0;There was another single-center randomized study involving 199 subjects (n treatment =100, n placebo = 99) evaluating oral and intravenous disopyramide versus placebo after&#x000a0;MI&#x000a0;found that prophylactic disopyramide does not reduce mortality after myocardial infarction.<xref ref-type="bibr" rid="article-20598.r11">[11]</xref> Furthermore, based on a systematic review and meta-analysis involving 44 clinical trials, according to the pooled analysis, disopyramide can increase mortality, although it is hard to translate this evidence to other populations due to the short follow-up duration of these clinical trials and that they involved mainly healthy subjects. Therefore, disopyramide is not used prophylactically for rhythm disturbances due to MI.<xref ref-type="bibr" rid="article-20598.r12">[12]</xref></p>
        <p>Disopyramide and other class I.A. antiarrhythmics also block the rapid component of the delayed rectifier potassium current when blocking the sodium channel resulting in&#x000a0;QT&#x000a0;interval prolongation.<xref ref-type="bibr" rid="article-20598.r13">[13]</xref>&#x000a0;Another effect displayed by disopyramide is AV node blocking with the prerequisite that the vagal tone has already&#x000a0;diminished by atropine. The heart will exhibit delay of av conduction resulting in bradycardia.</p>
      </sec>
      <sec id="article-20598.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Disopyramide is an orally administered drug in the form of capsules. There are two types of&#x000a0;capsule formulations contrasting with their drug delivery system property: the immediate-release and extended-release disopyramide. When using the standard release capsules, 200&#x000a0;to 300 mg of disopyramide is given as an initial dose, and 100 to 150 mg of disopyramide is given every 6 hours. Fewer initial dose and maintenance dose are needed for extended-release capsules because of&#x000a0;the formulation's extended half-life, and consequently, its duration of actions. However, extended-release capsules are usually avoided if&#x000a0;the clinician wants to achieve a rapid drug peak concentration.</p>
        <p>To promote less variation in peak and trough serum levels,&#x000a0;disopyramide should be administered around the clock (4 times per day; 12-6-12- 6, not 9-1-5-9). The controlled release capsules should not be broken nor chewed.</p>
        <p>Concerning its side effects, disopyramide must be started when the patient&#x000a0;is under in-hospital treatment except for patients without heart disease who have a normal QT interval.<xref ref-type="bibr" rid="article-20598.r4">[4]</xref>&#x000a0;Furthermore, In HOCM patients, initiation of disopyramide in the outpatient setting is safe, and the subsequent sudden cardiac death is low.<xref ref-type="bibr" rid="article-20598.r14">[14]</xref></p>
      </sec>
      <sec id="article-20598.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The main actions of disopyramide,&#x000a0;i.e.,&#x000a0;sodium channel blocking and anticholinergic properties, contribute to its side effects. The maximum rate of depolarization (MRD) decreases by preventing sodium channel entry, hence the reduced contractility of the myocardia.&#x000a0;The accompanying rapid component of delayed rectifier potassium channel blocking mentioned previously (see "Mechanism of Action")&#x000a0;also contributes to the increase of QT interval. Because of&#x000a0;these effects, disopyramide is excluded as a rhythm control treatment option for patients with overt heart failure (with systemic congestion) and long QT syndromes.<xref ref-type="bibr" rid="article-20598.r13">[13]</xref> Regarding its anticholinergic side effect, disopyramide can cause urinary retention.&#x000a0;Therefore, caution is advised, especially when using this agent for the elderly population in which benign prostate hypertrophy&#x000a0;is common. Other anticholinergic side effects of disopyramide usage are xerostomia, constipation, and glaucoma. Accordingly, to circumvent disopyramide's anticholinergic effects, pyridostigmine could be used.<xref ref-type="bibr" rid="article-20598.r15">[15]</xref></p>
        <p>Although rare (&#x0003c;1%), some have reported in case reports adverse events such as agranulocytosis, cholestatic jaundice, malignant arrhythmia, and other electrocardiographic abnormalities.<xref ref-type="bibr" rid="article-20598.r16">[16]</xref><xref ref-type="bibr" rid="article-20598.r17">[17]</xref><xref ref-type="bibr" rid="article-20598.r18">[18]</xref></p>
      </sec>
      <sec id="article-20598.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Several conditions stated below prevent the use of disopyramide as an antiarrhythmic drug:<xref ref-type="bibr" rid="article-20598.r2">[2]</xref><xref ref-type="bibr" rid="article-20598.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Overt heart failure; disopyramide is known to have negative inotropic effects resulting in decreased heart ejection fraction.</p>
          </list-item>
          <list-item>
            <p>Second or third-degree AV block without a pacemaker present; In a heart that is free from the influence of vagal tone, disopyramide can worsen the current AV conduction status.</p>
          </list-item>
          <list-item>
            <p>Long QT syndromes: disopyramide and other class Ia antiarrhythmics can prolong the QT interval.</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to the drugs itself or its components</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20598.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The cytochrome CYP3A4 is responsible for the liver metabolism of disopyramide. It can be induced or inhibited by various substances. Hence, these substances should be avoided or used cautiously to prevent the unpredictable modification of disopyramide pharmacokinetics. Listed below are several substances that are known to induce and inhibit CYP3A4.<xref ref-type="bibr" rid="article-20598.r2">[2]</xref></p>
        <p>CYP3A4 inducers (increase disopyramide metabolism, reducing the disopyramide's plasma half-life):</p>
        <list list-type="bullet">
          <list-item>
            <p>Rifampin</p>
          </list-item>
          <list-item>
            <p>Phenobarbital</p>
          </list-item>
          <list-item>
            <p>Phenytoin</p>
          </list-item>
        </list>
        <p>CYP3A4 inhibitors (decrease disopyramide metabolism, increasing the disopyramide's plasma half-life):</p>
        <list list-type="bullet">
          <list-item>
            <p>Verapamil</p>
          </list-item>
          <list-item>
            <p>Diltiazem</p>
          </list-item>
          <list-item>
            <p>Ketoconazole</p>
          </list-item>
          <list-item>
            <p>Macrolide antibiotics</p>
          </list-item>
          <list-item>
            <p>Protease-inhibitors</p>
          </list-item>
          <list-item>
            <p>Grapefruit juice</p>
          </list-item>
        </list>
        <p>If any of these substances will be used concurrently with disopyramide, monitoring disopyramide's plasma concentration is warranted to prevent adverse consequences.</p>
        <p>In patients with severe renal dysfunction (renal clearance of &#x0003c; 8mL/min), disopyramide's half-life is longer, and the duration ranges from 14&#x000a0;to 43 hours.<xref ref-type="bibr" rid="article-20598.r20">[20]</xref> Whereas disopyramide's plasma half-life in normal healthy adults ranges from 6&#x000a0;to 8 hours.<xref ref-type="bibr" rid="article-20598.r21">[21]</xref> Therefore, drug dose modification is warranted. This information is acquirable through the manufacturer's labeling. Moreover, in patients with hepatic impairment and heart failure, disopyramide's half-life is also increased.<xref ref-type="bibr" rid="article-20598.r17">[17]</xref>&#x000a0;Additionally, impairment of liver function can decrease alpha-1-acid-glycoprotein, a protein that binds disopyramide, causing free disopyramide concentrations to rise.<xref ref-type="bibr" rid="article-20598.r22">[22]</xref></p>
      </sec>
      <sec id="article-20598.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The safe ranges for therapeutic disopyramide concentrations are from 2&#x000a0;to 5 mg/mL. Of note, in a patient with cirrhosis, lower concentrations are preferable due to increase free form.<xref ref-type="bibr" rid="article-20598.r23">[23]</xref> When concentration is exceeding 9mg/mL, signs and symptoms of disopyramide toxicities will ensue.<xref ref-type="bibr" rid="article-20598.r24">[24]</xref><xref ref-type="bibr" rid="article-20598.r25">[25]</xref><xref ref-type="bibr" rid="article-20598.r26">[26]</xref></p>
        <p>Due to&#x000a0;relatively small&#x000a0;volume distribution (Vd), low protein binding at toxic concentrations, and low intrinsic clearance, extracorporeal drug removal techniques (hemoperfusion/ hemodialysis) can be useful to remove disopyramide from the circulation in the setting of intoxication.<xref ref-type="bibr" rid="article-20598.r27">[27]</xref></p>
        <p>Generally, the&#x000a0;initial&#x000a0;priority is&#x000a0;to decontaminate the patient's gastrointestinal system with lavage, repeat doses of oral activated charcoals, and cathartic. These are done even when several hours have passed since the first ingestion because it can significantly delay the absorption of class Ia antiarrhythmics. Followed by admission to the intensive care unit for continuous electrocardiographic monitoring. Hemodialysis/hemoperfusion can be useful if the patient has ingested large doses or with high drug concentration or in the setting of circulatory collapse or renal insufficiency. Symptomatic drugs should be given accordingly. For seizures, administration of diazepam, phenytoin, or phenobarbital can be useful. In hypotensive patients, fluid challenge and intravenous inotropic and vasopressor agents should be used, and mechanical supports such as intra-aortic balloon pumps or cardiopulmonary bypass are taken into consideration in refractory cardiogenic shock. Lastly, in the setting of arrhythmia, whether it is bradyarrhythmia or ventricular tachycardia (torsade de pointes), the appropriate medication should be given.<xref ref-type="bibr" rid="article-20598.r17">[17]</xref>&#x000a0;&#x000a0;</p>
        <p>Although only based on theoretical considerations, NaHCO3 50 mmol can be given intravenously and repeated&#x000a0;every&#x000a0;5&#x000a0;to 10 minutes. The main goal is to maintain the arterial pH&#x000a0;at 7.4 to 7.5. The drug reversal mechanism possibly multifactorial, such as increasing blood pH, increasing blood plasma sodium concentration, and lowering plasma potassium concentration.<xref ref-type="bibr" rid="article-20598.r17">[17]</xref></p>
      </sec>
      <sec id="article-20598.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>With a&#x000a0;wide variety of drugs available to treat heart rhythm abnormalities and substantial information regarding them, a newly graduated physician or junior doctor can&#x000a0;become overwhelmed&#x000a0;regarding which agent to use, especially among the older agents. This is why antiarrhythmic therapy should utilize the efforts of an interprofessional healthcare team. With help&#x000a0;from a pharmacist, a doctor can choose&#x000a0;whether disopyramide is indicated or&#x000a0;contraindicated to use based&#x000a0;on the patient's unique characteristics. When disopyramide has already been administered, a coordinative effort between the clinician and a nurse is necessary. A nurse can notify the ordering clinician regarding the patient's response to the drug, whether other agents are needed or not, and when side effects/adverse events prevent its use.&#x000a0;These are just a few examples of why&#x000a0;a collaborative approach of the interprofessional healthcare team is needed. The use of disopyramide is already approved by several guidelines (HRA/AHA/ACC/EHRS), and its indicated as a third-line agent for the treatment of life-threatening arrhythmia (VT/VF) and&#x000a0;atrial fibrillation, especially sleep-induced or vagal induced.<xref ref-type="bibr" rid="article-20598.r2">[2]</xref><xref ref-type="bibr" rid="article-20598.r13">[13]</xref><xref ref-type="bibr" rid="article-20598.r19">[19]</xref>&#x000a0;[Level 5] It can also&#x000a0;be used in HOCM with a combination of beta-blocker.<xref ref-type="bibr" rid="article-20598.r5">[5]</xref>&#x000a0;[Level 3]</p>
      </sec>
      <sec id="article-20598.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20598&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20598">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20598/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20598">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20598.s11">
        <fig id="article-20598.image.f1" position="float" orientation="portrait">
          <caption>
            <p>This image depict the molecular structure of disopyramide Contributed by Wikimedia User: Hengsheng120 (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Disopramide" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-20598.s12">
        <fig id="article-20598.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Drugs affecting the cardiac action potential. The sharp rise in voltage ("0") corresponds to the influx of sodium ions, whereas the two decays ("1" and "3", respectively) correspond to the sodium-channel inactivation and the repolarizing efflux of potassium ions. The characteristic plateau ("2") results from the opening of voltage-sensitive calcium channels. Contributed by Wikimedia User: Architha Srinivasan (CC BY-SA 4.0 https://creativecommons.org/licenses/by-sa/4.0/deed.en)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Cardiac_action_potential" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20598.s13">
        <title>References</title>
        <ref id="article-20598.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MOKLER</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>VAN ARMAN</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of a new antiarrhythmic agent, gamma-diisopropyl-amino-alpha-phenyl-alpha-(2-pyridyl)-butyramide (SC-7031).</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1962</year>
            <month>Apr</month>
            <volume>136</volume>
            <fpage>114</fpage>
            <page-range>114-24</page-range>
            <pub-id pub-id-type="pmid">14475124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>64</volume>
            <issue>21</issue>
            <fpage>e1</fpage>
            <page-range>e1-76</page-range>
            <pub-id pub-id-type="pmid">24685669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuster</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ryd&#x000e9;n</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Cannom</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Crijns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ellenbogen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Le Heuzey</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Prystowsky</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deckers</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Despres</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dickstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lekakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Metra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Osterspey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
              <collab>European Society of Cardiology Committee for Practice Guidelines</collab>
              <collab>European Heart Rhythm Association</collab>
              <collab>Heart Rhythm Society</collab>
            </person-group>
            <article-title>ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Aug</month>
            <day>15</day>
            <volume>114</volume>
            <issue>7</issue>
            <fpage>e257</fpage>
            <page-range>e257-354</page-range>
            <pub-id pub-id-type="pmid">16908781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuster</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ryd&#x000e9;n</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Asinger</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cannom</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Crijns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Frye</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>L&#x000e9;vy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McNamara</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Prystowsky</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Wyse</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Faxon</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Fuster</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gregoratos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hiratzka</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Alonso-Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>de Backer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Flather</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hradec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
              <collab>European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation)</collab>
              <collab>North American Society of Pacing and Electrophysiology</collab>
            </person-group>
            <article-title>ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.</article-title>
            <source>Circulation</source>
            <year>2001</year>
            <month>Oct</month>
            <day>23</day>
            <volume>104</volume>
            <issue>17</issue>
            <fpage>2118</fpage>
            <page-range>2118-50</page-range>
            <pub-id pub-id-type="pmid">11673357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherrid</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Barac</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Dickie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chojnowska</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2005</year>
            <month>Apr</month>
            <day>19</day>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1251</fpage>
            <page-range>1251-8</page-range>
            <pub-id pub-id-type="pmid">15837258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dan</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Martinez-Rubio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boriani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Borggrefe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gaita</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Gelder</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Okumura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Potpara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poulsen</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savelieva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wolpert</surname>
                <given-names>C</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).</article-title>
            <source>Europace</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>731</fpage>
            <page-range>731-732an</page-range>
            <pub-id pub-id-type="pmid">29438514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karlson</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Torstensson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Abj&#x000f6;rn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.</article-title>
            <source>Eur Heart J</source>
            <year>1988</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-90</page-range>
            <pub-id pub-id-type="pmid">3289932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughan Williams</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>A classification of antiarrhythmic actions reassessed after a decade of new drugs.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>129</fpage>
            <page-range>129-47</page-range>
            <pub-id pub-id-type="pmid">6144698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sasyniuk</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Electrophysiological actions of disopyramide phosphate on canine ventricular muscle and purkinje fibers.</article-title>
            <source>Circ Res</source>
            <year>1975</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>844</fpage>
            <page-range>844-54</page-range>
            <pub-id pub-id-type="pmid">1192576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <article-title>Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.</article-title>
            <source>Postgrad Med J</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>60</volume>
            <issue>700</issue>
            <fpage>98</fpage>
            <page-range>98-107</page-range>
            <pub-id pub-id-type="pmid">6369290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicholls</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Haybyrne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Intravenous and oral disopyramide after myocardial infarction.</article-title>
            <source>Lancet</source>
            <year>1980</year>
            <month>Nov</month>
            <day>01</day>
            <volume>2</volume>
            <issue>8201</issue>
            <fpage>936</fpage>
            <page-range>936-8</page-range>
            <pub-id pub-id-type="pmid">6107587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lafuente-Lafuente</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valembois</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Belmin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Mar</month>
            <day>28</day>
            <issue>3</issue>
            <fpage>CD005049</fpage>
            <pub-id pub-id-type="pmid">25820938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Priori</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mazzanti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borggrefe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Fitzsimons</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hatala</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hindricks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuck</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hernandez-Madrid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nikolaou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Norekv&#x000e5;l</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Spaulding</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Nov</month>
            <day>01</day>
            <volume>36</volume>
            <issue>41</issue>
            <fpage>2793</fpage>
            <page-range>2793-2867</page-range>
            <pub-id pub-id-type="pmid">26320108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fourey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weissler-Snir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hindieh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gollob</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rakowski</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2017</year>
            <month>May</month>
            <day>26</day>
            <volume>6</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28550094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherrid</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Arabadjian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2012</year>
            <season>May-Jun</season>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>483</fpage>
            <page-range>483-92</page-range>
            <pub-id pub-id-type="pmid">22687589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conrad</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Cumbie</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Thrasher</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Agranulocytosis associated with disopyramide therapy.</article-title>
            <source>JAMA</source>
            <year>1978</year>
            <month>Oct</month>
            <day>20</day>
            <volume>240</volume>
            <issue>17</issue>
            <fpage>1857</fpage>
            <page-range>1857-8</page-range>
            <pub-id pub-id-type="pmid">691193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Benowitz</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.</article-title>
            <source>Drug Saf</source>
            <year>1990</year>
            <season>Nov-Dec</season>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>393</fpage>
            <page-range>393-420</page-range>
            <pub-id pub-id-type="pmid">2285495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edmonds</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hayler</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>A case of intra-hepatic cholestasis after disopyramide therapy.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-6</page-range>
            <pub-id pub-id-type="pmid">7439249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benussi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahlsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casadei</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Castella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Heidbuchel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hendriks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hindricks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Oldgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Schotten</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Van Putte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vardas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baron Esquivias</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Budts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Carerj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casselman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Caterina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Deftereos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dobrev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fitzsimons</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guenoun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hohnloser</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kolh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rosenhek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Savelieva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suwalski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Van Gelder</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Voors</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zeppenfeld</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.</article-title>
            <source>Europace</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>1609</fpage>
            <page-range>1609-1678</page-range>
            <pub-id pub-id-type="pmid">27567465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whiting</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Disopyramide in renal impairment.</article-title>
            <source>Lancet</source>
            <year>1977</year>
            <month>Dec</month>
            <day>24-31</day>
            <volume>2</volume>
            <issue>8052-8053</issue>
            <fpage>1363</fpage>
            <pub-id pub-id-type="pmid">74774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Whiting</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1978</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>409</fpage>
            <page-range>409-19</page-range>
            <pub-id pub-id-type="pmid">728284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonde</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graudal</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Balsl&#x000f8;v</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Angelo</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Svendsen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Kampmann</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Kinetics of disopyramide in decreased hepatic function.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1986</year>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-7</page-range>
            <pub-id pub-id-type="pmid">3780831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Echizen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Umeda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ishizaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1986</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-80</page-range>
            <pub-id pub-id-type="pmid">3742934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gosselin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chopin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wattel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haguenoer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Desprez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acute intoxication with diisopyramide: clinical and experimental study by hemoperfusion an Amberlite XAD 4 resin.</article-title>
            <source>Clin Toxicol</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>439</fpage>
            <page-range>439-49</page-range>
            <pub-id pub-id-type="pmid">7449357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayler</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Volans</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Fatal overdosage with disopyramide.</article-title>
            <source>Lancet</source>
            <year>1978</year>
            <month>May</month>
            <day>06</day>
            <volume>1</volume>
            <issue>8071</issue>
            <fpage>968</fpage>
            <page-range>968-9</page-range>
            <pub-id pub-id-type="pmid">76895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sathyavagiswaran</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fatal disopyramide intoxication from suicidal/accidental overdose.</article-title>
            <source>J Forensic Sci</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>1813</fpage>
            <page-range>1813-8</page-range>
            <pub-id pub-id-type="pmid">3323413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20598.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinderling</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Garrett</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.</article-title>
            <source>J Pharmacokinet Biopharm</source>
            <year>1976</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-230</page-range>
            <pub-id pub-id-type="pmid">978389</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
